• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • US nod for CSL Behring’s Hizentra pharmatimes
    July 23, 2018
    US regulators have cleared CSL Behring’s Hizentra for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder affecting the peripheral nerves that can cause permanent nerve damage.
  • FDA Approves Hizentra americanpharmaceuticalreview
    March 19, 2018
    CSL Behring announced the U.S. Food and Drug Administration (FDA) approved Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service